91 related articles for article (PubMed ID: 12722404)
1. [Evaluation of serum sICAM-1 amd CA-125 in patients with ovarian tumors--preliminary report].
Rzymski P; Woźniak J; Opala T; Sajdak S; Drews K
Ginekol Pol; 2002 Nov; 73(11):1090-5. PubMed ID: 12722404
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of soluble intracellular adhesion molecule-1 (sICAM-1) in women with benign ovarian tumors].
Rzymski P; Opala T; Woźniak J; Drews K; Sajdak S
Ginekol Pol; 2004 Oct; 75(10):785-92. PubMed ID: 15587910
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of soluble intracellular adhesion molecule-1 (sICAM-1) in benign and malignant ovarian masses.
Opala T; Drews K; Rzymski P; Woźniak J; Sajdak S
Eur J Gynaecol Oncol; 2003; 24(3-4):255-7. PubMed ID: 12807235
[TBL] [Abstract][Full Text] [Related]
4. Serum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers.
Callet N; Delaunay J; Pichon MF
Eur J Gynaecol Oncol; 2000; 21(2):135-40. PubMed ID: 10843471
[TBL] [Abstract][Full Text] [Related]
5. Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions.
Altomonte M; Fonsatti E; Lamaj E; Cattarossi I; Cattelan A; Maio M
Breast Cancer Res Treat; 1999 Nov; 58(1):19-23. PubMed ID: 10634514
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of the morphological ultrasound score system and the serum concentration of CA 125 in the diagnosis of malignant ovarian cancer].
Brazert J; Pietryga M; Szabłoński W; Persona-Sliwińska A; Biczysko R
Ginekol Pol; 2003 Dec; 74(12):1542-8. PubMed ID: 15029747
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with colorectal cancer.
Kang X; Wang F; Xie JD; Cao J; Xian PZ
World J Gastroenterol; 2005 Jul; 11(27):4250-3. PubMed ID: 16015700
[TBL] [Abstract][Full Text] [Related]
8. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
9. [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients].
Grabiec M; Nowicki P; Walentowicz M; Greźlikowska U; Mierzwa T; Chmielewska W
Ginekol Pol; 2005 May; 76(5):371-6. PubMed ID: 16145856
[TBL] [Abstract][Full Text] [Related]
10. The serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble gp130 (sgp130) in different tumour stages. Correlation between the two parameters in progression of malignancy.
Kovacs E
Biomed Pharmacother; 2005 Oct; 59(9):498-500. PubMed ID: 16202558
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
12. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
13. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
14. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
[TBL] [Abstract][Full Text] [Related]
15. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
16. [Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients].
Grzybowski W; Beta J; Fritz A; Durczyński A; Bidziński M; Grabiec M; Jakimiuk AJ
Ginekol Pol; 2010 Jul; 81(7):511-5. PubMed ID: 20825052
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
18. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
Van Calster B; Timmerman D; Bourne T; Testa AC; Van Holsbeke C; Domali E; Jurkovic D; Neven P; Van Huffel S; Valentin L
J Natl Cancer Inst; 2007 Nov; 99(22):1706-14. PubMed ID: 18000221
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]